• Athuf Thaha Sub Bagian Alergi/ Imunologi Departemen Ilmu Kesehatan Kulit & Kelamin FK UNSRI/ RS dr. M. Hoesin Palembang




Treatment  limitations  of  current  immunosuppressive  therapies,  and  growing  understanding  of  psoriasis
pathogenesis on a molecular level have stimulated much interest in the field of immunomodulatory therapy fo
management of psoriasis. Genetic engineering has allowed the development of proteins that are targeted to
specific cell surface receptors. A well over 40 targeted biologic agents are in preclinical and clinical testing fo
T-cell  mediated  inflammatory    diseases,  including  psoriasis.  It  is  important  that,  as  a  doctor  become  wel
educated in biologics, since several of these agents are available for the management of psoriasis.   
Keywords:  immunosuppressive  therapy,  immunomodulatory  therapy,  genetic  engineering,  surface  receptors,  targeted
biologic agents, biologics.


Download data is not yet available.


Kruger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. Continuing Medical Education. J Am Acad Dermatol 2002;46:1-23.

Gordon KB, West DT. Biologic therapy in psoriasis. In: S. Wolverton, ed. Comprehensive Dermatologic Drug Therapy.Philadelphia, PA: WB Saunders Co;2001:928-942

Pariser DM. Treating Psoriasis Patients with biologic agents. Improved outcomes with new biologic agents are prompting physicians to intergrate them into therapy for psoriasis patients. MANAGE CARE, 2003.

Winhoven SM. and Griffiths CEM. Biologics for Psoriasis. The Dermatology Centre, The University of Manchester, Hope Hospital, Manchester, UK, 2005.

Vaishnaw AK, Ticho B. Alefacept is efficacious in a broadspectrum of patients with psoriasis, including those with severe disease.Presented at the 61stAnnual Meeting of the American Academy of Dermatology; March21-26, 2003; San Fransisco.

Cather JC, Cather JC, and Menter A. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther 2003;3(2):361-370

Hitt E. Efalizumab withdrawn from US market. Available from: http://www.medscape.com/viewarticle/590862?src=mp&spon=33&uac=91557DY. (Cited 2009 April 15).

Gottlieb AB, Li S, Evans R, et al. Infliximab in the treatment of psoriasis: Results from the first 10 weeks of the phase II trial. Presented at the 61stAnnual Meeting of the American Academy of Dermatology; March 21-26, 2003; San Fransisco.

Leonardi C, Gottlieb AB, Zitnik R, et al. Efficacy and safety of ENBREL., (etanercept) in patients with psoriasis: Results of phase III study.Presented at International Investigative Dermatology 2003; April30-May 4, 2003; Miami Beach.

Gordon KB, Blum RR, Papp KA, et al. Efficacy and Safety of Adalimumab Treatment in Patients with moderate to severe Psoriasis: A Double-Blind, Randomized Clinical Trial.Psoriasis Forum, Summer 2007;13(1):4-11

Emery P, Davis Jr JC, Klareskog L, Westhovens R. Selective Costimulatory Modulators: Addressing Unmet Needs in Rhematoid Arthritis management. Available from: http://www.medscape.com/viewarticle/496108_13. (Cited 2008 December 14) 12. Vincenti F. Costimulation blockade-what will the future bring?.Nephrol Dial Transpl 2007;22(5):1293-1296.

Walsh SRA, Shear NH. Psoriasis and the new biologic agents: interruptinga T-AP dance. CMAJ • June 22, 2004; 170 (13):1933-1941

Feldman SR. What’s New in Psoriasis Treatment ?.Available from: http://www.medscape.com/viewarticle/412777. (Cited 2008 January 18).

Sterry KAW, Volk HD. Interleukin-10 Therapy-Review of a New Approach. Pharmacol Rev 2003;55:241-269

Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). The Lancet 2008;371(9625):1675-1684.

Schmidt, C. Ustekinumab poised to enter the psoriasis market. Nat Biotechnol 2008; 26:1317

Kimball, AB, Gordon, KB, Langley, RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results ofa randomized, placebo-controlled, phase 2 trial.Arch Dermatol 2008; 144:200.






Research Article